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Background. Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by an increase in pulmonary
artery pressure leading to right ventricular (RV) hypertrophy, RV failure, and ultimately death. Current treatments can improve
symptoms and reduce severity of the hemodynamic disorder but gradual deterioration in their condition often necessitates a lung
transplant. Methods and Results. In experimental models of PAH, particularly the model of monocrotaline-induced pulmonary
hypertension, eﬃcacious treatment options tested so far include a spectrum of pharmacologic agents with actions such as anti-
mitogenic, proendothelial function, proangiogenic, antiinﬂammatory and antioxidative. Emerging trends in PAH treatment are
gene and cell therapy and their combination, like (progenitor) cells enriched with eNOS or VEGF gene. More animal data should
be collected to investigate optimal cell type, in vitro cell transduction, route of administration, and number of cells to inject.
Several recently discovered and experimentally tested interventions bear potential for therapeutic purposes in humans or have
been shown already to be eﬀective in PAH patients leading to improved life expectation and better quality of life. Conclusion.
Since many patients remain symptomatic despite therapy, we should encourage research in animal models of PAH and implement
promising treatments in homogeneous groups of PAH patients.
1.Background
1.1. Pulmonary Arterial Hypertension. Pulmonary arterial
hypertension (PAH) is a progressive condition characterized
by elevated pulmonary arterial pressures leading to RV
failure. PAH is primarily a lung disorder associated with
increased pulmonary vascular resistance, pulmonary vascu-
lar pathology, medial hypertrophy of arterioles, and lung
inﬂammation. PAH may occur in association with underly-
ing collagen vascular disease, congenital heart disease, HIV
infection, or chronic thromboembolic disease. A minority
of patients with PAH have idiopathic PAH. In familial PAH,
70% of the cases have heterozygous mutations of BMPR2
encoding the bone morphogenetic protein receptor type 2
[1].
Current therapeutic strategies may improve symptoms
and reduce the severity of the hemodynamic disorder, but
in many cases deterioration of pulmonary and cardiac
functions ultimately necessitates a lung transplant. Novel
approaches in treating PAH include: (1) reversing the
advanced occlusive structural changes in the pulmonary
circulation that cause PAH and (2) regeneration of damaged
pulmonary tissue using stem cells. These approaches have
been tested using (i) pharmacotherapy, (ii) gene therapy, and
(iii) cell therapy.
1.2. Animal Models of Pulmonary Arterial Hypertension. Var-
ious experimental models have been proposed for induction
of PAH in animals including: (1) monocrotaline- (MCT-)
induced PAH with or without aortocaval shunt; (2) chronic
hypoxia-induced PAH; (3) chronic embolism-induced PAH;
(4) ligation of ductus arteriosus; (5) overcirculation-induced
PH; (6) genetically modiﬁed animal models, such as mice
lacking the vasoactive intestinal peptide (VIP) gene. In the
past 10 years most experimental studies on therapy of PAH
have employed the MCT-induced PAH model.2 Journal of Biomedicine and Biotechnology
2. Treatment Options for PAH
2.1. Pharmacotherapy. Several pharmacologic agents have
been used either alone or in combination to treat PAH.
2.1.1. Serine Elastase Inhibitors. Progression of PAH is asso-
ciated with increased serine elastase activity and deposition
of extracellular matrix (ECM) protein tenascin-C in lung
parenchyme. The recent studies using hypertrophied rat
pulmonary arteries have shown that elastase inhibitors
suppresstenascin-Candinduceapoptosisofvascularsmooth
muscle cells (SMCs) [2, 3]. This therapy initiates complete
regression of the hypertrophied vessel wall by a coordinated
lossofcellularityandECM.Elastaseinhibitorswereshownto
reverse advanced MCT-induced pulmonary vascular disease.
If the serine elastase inhibitors M249314 or ZD0892 were
orally administered from 21 days after injection of MCT
onwards, survival after 1 week was 92%, compared with only
39% survival in untreated or vehicle-treated rats [4].
2.1.2. Platelet-Derived Growth Factor Inhibition. Progression
of PAH is associated with increased proliferation and migra-
tion of pulmonary vascular SMCs. Platelet-derived growth
factor (PDGF) is a potent mitogen involved in this process.
In rats with MCT-induced PAH daily administration of the
PDGF receptor antagonist STI571 (imatinib) was started 28
days after disease induction, resulting in 100% survival in
the ﬁrst 2 weeks, compared with only 50% in shamtreated
rats. PAH and RV hypertrophy were reversed to near-normal
levels. Similar results were obtained in chronically hypoxic
mice treated with STI571 after full establishment of PAH
[5].
2.1.3. Prostacyclin Therapy. Rats with ﬂow-associated
PAH due to an aortocaval shunt, in combination with
MCT administration, were treated with low-dose aspirin
(25mg/kg/day) or iloprost (72μg/kg/day), a prostacyclin
analogue. 90% of the untreated rats with PAH developed
dyspnea and pleural ﬂuid; whereas this was seen in 50% and
10% of the aspirin and iloprost-treated rats, respectively.
This could not be attributed to changes in pulmonary artery
pressure, wall to lumen ratio of the pulmonary arterioles,
or RV hypertrophy. However, both therapies restored the
reduced RV capillary to cardiomyocyte ratio in rats with
PAH and improved RV contractility [6]. Subcutaneous
administration of a novel prostacyclin agonist (ONO-1301)
markedly attenuated MCT-induced PAH and improved
survival in rats. The beneﬁcial eﬀects of ONO-1301 occurred
through its long-lasting stimulation of cAMP and inhibition
of thromboxane synthase [7].
Although prostacyclin is recognized as a therapeutic
breakthrough for PAH, it needs continuous infusion because
of its short half-life in plasma. To overcome this problem,
a new drug delivery system was developed by preparing
ONO-1301MS, a novel sustained-release prostacyclin ana-
logue polymerized with poly (D,L-lactic-co-glycolic acid)
microspheres. A single injection of ONO-1301MS resulted
in sustained activity for 3 weeks, and attenuated PAH, partly
through its antiproliferative eﬀect on vascular SMCs via
inhibition of ERK phosphorylation [8]. Also the inhalation
of iloprost has been shown to reverse PAH and vascular
structural remodeling in MCT-treated rats [9].
2.1.4. Combined Prostacyclin and Phosphodiesterase Inhibi-
tion. Combination therapy with oral sildenaﬁl, a phos-
phodiesterase (PDE)-5 inhibitor, and beraprost, an oral
prostacyclin analogue, attenuated the development of MCT-
induced PAH more than with either drug alone [10].
The combined administration of iloprost, a long-acting
prostacyclinanalogue, and a dual-selective PDE3/4 inhibitor,
tolafentrine, reversed the development of PAH and cor
pulmonale in response to MCT in rats [11].
2.1.5. Rho-Kinase Inhibition. Long-term treatment with a
Rho-kinase inhibitor fasudil improved the mortality rate
of MCT-induced PAH in rats [12], as well as ameliorated
hypoxia-induced PAH in mice, partially by activation of
endothelial nitric oxide synthase (eNOS) [13]. Fasudil exerts
eﬀectiveandselectivevasodilatationofpulmonaryarteriesin
rats with MCT-induced PAH, which explains its usefulness
for the treatment of this fatal disorder [14]. In chronicly
hypoxic rats, inhalation of Rho-kinase inhibitors nearly
normalized PAH, but had no pulmonary vascular selectivity
[15].
2.1.6. Combined Rho-Kinase Inhibitor and Prostacyclin Ther-
apy. Combination therapy has been advocated based on
potential for additive or synergistic eﬀects. Long-term inhi-
bition of Rho-kinase, an eﬀector of the small GTPase Rho,
amelioratedMCT-inducedPAHinratsandhypoxia-induced
PAH in mice. It was reported that prostacyclin and its oral
analogue beraprost may lack direct inhibitory eﬀect on Rho-
kinase in vitro, suggesting that combination therapy with a
Rho-kinase inhibitor and beraprost is eﬀective for the treat-
ment of PAH. Male rats were given a subcutaneous injection
of MCT (60mg/kg) and were subsequently treated without
or with a Rho-kinase inhibitor (fasudil, 30mg/kg/day),
beraprost (200mg/kg/day), or a combination of both for 3
weeks. The combination therapy, when compared with each
monotherapy, showed signiﬁcant improvement in PAH, RV
hypertrophy, and pulmonary medial thickness without any
adverse eﬀects [16].
2.1.7. Endothelin Receptor Antagonists. Endothelin-1 (ET-
1), a potent vasoactive and mitogenic peptide, has been
implicated in the pathogenesis of several forms of PAH.
A nonspeciﬁc endothelin-receptor antagonist, bosentan was
shown to blunt MCT-induced PAH in rats [17].
The antagonism of the ETA receptor was shown to
be essential for the protection from MCT-induced PAH,
irrespective of the presence of the ETB receptors, although
ap r o t e c t i v er o l eo fE T B receptor-mediated action in the
pathogenesis of this disease model could not be ruled out
[18].Journal of Biomedicine and Biotechnology 3
In another study from the same group, the functional
roles of endothelin ETA and ETB receptors in the develop-
ment of MCT-induced PAH were investigated using MCT-
treated rats with or without daily administration of A-
192621, a selective ETB receptor antagonist, ABT-627, a
selective ETA receptor antagonist, or a combination of both.
The results demonstrated that the ETA receptor-mediated
action contributed exclusively to the pathogenesis of MCT-
induced PAH [19].
2.1.8. Combined Endothelin-A Receptor Antagonist and
Prostacyclin Therapy. Rats with MCT-induced PAH were
treated with the oral ETA receptor antagonist TA-0201
and/or the oral prostacyclin analogue beraprost for 19
days. The PAH-associated RV systolic pressure elevation
was signiﬁcantly attenuated by TA-0201 and beraprost, and
most strongly by their combination. The indexes of RV
hypertrophy showed the same tendency as the increase in RV
peak systolic pressure [20].
2.1.9. Serotonin Transporter Inhibition. Progression of PAH
is associated with increased pulmonary expression of the
serotonin transporter (5-HTT), which leads to hyperplasia
of the pulmonary artery SMCs (PA-SMCs). Given the fact
that overexpression of the 5-HTT gene in PA-SMCs leads to
PAH [21], it was investigated whether the highly selective
5-HTT inhibitor ﬂuoxetine prevented and/or reversed PAH
in MCT-treated rats. Selective antagonists to the 5-HT1B/1D
receptor, 5-HT2A receptor, and 5-HT2B receptor were used
for comparative testing. MCT injection (60mg/kg s.c.) was
followed by an early peak in lung 5-HTT expression on
day 1, which preceded the onset of PAH. Established PAH
on day 15 was associated with a sustained 5-HTT increase.
Continued ﬂuoxetine treatment completely prevented PA-
SMC proliferation and PAH development, and also sup-
pressed the late 5-HTT increase, without aﬀecting the early
peak. The 5-HT receptor antagonists did not aﬀect PAH.
Oral ﬂuoxetine (10mg/kg/day) started 3 weeks after MCT
injection completely reversed established PAH, normalizing
pulmonary artery pressure and structure [22].
Furthermore, a selective serotonin reuptake inhibitor,
sertraline, protects against MCT-induced PAH by decreasing
pulmonary artery pressure, RV hypertrophy index, and pul-
monary artery remodeling, probably related to a reduction
in serotonin transporter mRNA [23].
A serotonin receptor antagonist, MCI-9042, attenuated
the development of MCT-induced PAH, suggesting a pivotal
role of serotonin in the development of PAH induced by
MCT [24].
Speciﬁc 5-HT2A receptor blockade with sarpogrelate,
a 5-HT2A receptor antagonist, immediately after MCT
administration, inhibited PAH and prolonged survival in
rats. These eﬀects were accompanied by anti-inﬂammatory
and antiproliferative eﬀects in the lung tissue and marked
improvementofpulmonaryvascularendothelialdysfunction
and activation [25].
2.1.10. Phosphodiesterase Inhibition. PDE inhibitors for
treatment of PAH have been studied extensively. Oral
sildenaﬁl, a PDE5 inhibitor, prevented (in a study in which
sildenaﬁl was given 1 day after MCT) and reversed (in a
study in which sildenaﬁl was given 3 weeks after MCT)
the development of PAH in MCT-treated rats, associated
with a reduction in the ETA-receptor density in SMCs
of pulmonary small arteries (diameter < 100μm) [26].
The eﬀects of oral pumafentrine, a mixed-selective PDE3/4
inhibitor, have been investigated in rats with MCT-induced
PAH. When chronically administered in weeks 4 to 6
after a single injection of MCT (60mg/kg), pumafentrine
(10mg/kg daily) partially reversed PAH and RV hyper-
trophy in rats [27]. In addition, small pulmonary arte-
rial muscularization, medial hypertrophy, and decrease in
lumen area were largely reversed. Inhibition of PA-SMC
proliferation by pumafentrine was demonstrated in vivo
[27].
Four weeks after a single injection of MCT in rats,
the animals displayed nearly threefold elevated pulmonary
artery pressure and vascular resistance values, with a con-
comitant decline in central venous oxygen saturation and
arterial oxygenation. Marked RV hypertrophy was evident,
and massive thickening of the arteriolar SMC layer was
histologically apparent. Sildenaﬁl, administered from day
14 to day 28, signiﬁcantly increased plasma cGMP and
inhibited the development of PAH and RV hypertrophy,
with improvement of central venous oxygen saturation and
arterial oxygenation. A corresponding eﬃcacy proﬁle was
also noted for treatment with sildenaﬁl started at day 28 till
day 42. Moreover, the death rate signiﬁcantly decreased in
those animals treated with sildenaﬁl [28].
Inhalation of tolafentrine, a combined PDE3/4 inhibitor,
reversed PAH that occurred in response to MCT in rats.
This “reverse remodeling” eﬀect included structural changes
in the lung vascular wall and key molecular pathways of
matrix regulation, concomitant with 60% normalization of
hemodynamics [29].
2.1.11. Combination of Phosphodiesterase and Endothelin
Receptor Inhibition. In a study with 5 groups of rats, a ﬁrst
group consisted of control rats without MCT injection. Four
other groups of rats received MCT subcutaneously and were
assigned to receive no treatment, 300mg/kg/day bosentan
in the food, 100mg/kg/day sildenaﬁl in drinking water, or
their combination for 4 weeks. The doses of bosentan and
sildenaﬁl were the maximally eﬀective doses based on a
dose-rangeﬁnding study. Mortality was 0%, 53%, 11%, 11%,
and 0%, respectively, in the ﬁve diﬀerent groups. Bosentan
and sildenaﬁl signiﬁcantly attenuated the increase in mean
pulmonary arterial pressure, and the combination had an
additional eﬀect [30].
2.1.12. Caveolin-1 Peptide. Caveolins, the principal struc-
tural proteins of caveolar microdomains, have been impli-
cated in the development of PAH. Mice with homozygous
deletion of the caveolin-1 (Cav-1)g e n ed e v e l o pP A Ha n d
RV hypertrophy. In several animal models of PAH and in
patients with severe PAH, reductions in pulmonary Cav-1
expression were apparent.4 Journal of Biomedicine and Biotechnology
TostudywhetherinvivomodulationofCav-1expression
could aﬀect the development of PAH and RV hypertrophy,
rats were injected with MCT, followed by a daily injection of
(1) saline, (2) a peptide corresponding to the homeodomain
of the Drosophila transcription factor antennapedia (AP;
2.5mg/kg/day), or (3) a peptide consisting of the Cav-1–
scaﬀolding domain coupled to AP (AP-Cav; 2.5mg/kg/day)
for 2 weeks. MCT and MCT+AP rats developed PAH.
Administration of AP-Cav to MCT rats signiﬁcantly reduced
the pulmonary artery pressure. MCT and MCT+AP rats also
developed pulmonary artery medial hypertrophy and RV
hypertrophy,whichwasnormalizedbyadministrationofAP-
Cav [31].
2.1.13. Estradiol. Daily supplementation of genistein, a
phytoestrogen, potently attenuated MCT-induced PAH, RV
hypertrophy, and pulmonary vascular remodeling in rats
[32]. Also 2-methoxyestradiol (2ME), a nonestrogenic estra-
diol metabolite, prevented the development and retarded the
progression of MCT-induced PAH [33]. 2ME signiﬁcantly
attenuated RV hypertrophy and pulmonary arterial medial
hypertrophy and reduced proliferative and inﬂammatory
responses in the lungs. Furthermore, 2ME given from day 14
to 28 to diseased animals signiﬁcantly decreased RV pressure
and RV hypertrophy and reduced mortality [33, 34].
Recently, it was shown that 2-ethoxyestradiol strongly
inhibits vascular remodeling in PAH which suggests that
antiproliferative agents, including synthetic analogues of
estradiol metabolites, may be protective in PAH [35].
2.1.14. Statins. Various statins have been shown to be eﬀec-
tive in treating experimental PAH. Simvastatin attenuated
MCT-induced pulmonary vascular remodeling, PAH, and
RV hypertrophy in rats [36]. Pravastatin reduced the devel-
opment of MCT-induced PAH and improved endothelium-
dependent pulmonary artery relaxation through reduced
apoptosis and a restored eNOS expression of endothelial
cells [37]. Rosuvastatin provided protection against the
development of PAH and RV hypertrophy [38].
2.1.15. Miscellaneous Therapeutic Agents. (1)Amlodipine,
a third-generation calcium channel blocker, inhibited the
development of PAH and improved survival in rats inde-
pendent of its eﬀect on lowering blood pressure. These
eﬀects were associated with marked inhibition of the
downregulation of eNOS and improvement of pulmonary
vascular endothelial activation, as well as anti-inﬂammatory,
antiproliferative, and antiﬁbrotic eﬀects in the lung tissue.
However, amlodipine failed to reverse established PAH [39].
(2) Nicorandil, an ATP-sensitive potassium channel
opener with a nitrate-like action, inhibited development of
MCT-induced PAH but failed to reverse it. These eﬀects were
associated with marked upregulation of diminished lung
eNOS concentration along with improvement of pulmonary
vascular endothelial activation and antiinﬂammatory and
anti-proliferative eﬀects in the lung tissue [40].
(3) Infusion of C-type natriuretic peptide, the third
member of the natriuretic peptide family, attenuated MCT-
induced PAH and improved survival. The beneﬁcial eﬀects
were mediated by regeneration of pulmonary endothelium,
inhibition of endothelial cell apoptosis, prevention of mono-
cyte/macrophage inﬁltration, and restoration of ﬁbrinolytic
activity [41].
(4) Repeated inhalation of adrenomedullin,ap o t e n t
vasodilator peptide that was originally isolated from human
pheochromocytoma, has been shown to inhibit MCT-
induced PAH without systemic hypotension, and thereby
improving survival in MCT rats [42].
(5) Heme oxygenase-1 was shown to be critical for the
antiproliferative and vascular protective eﬀects of rapamycin,
an immunosuppressive agent with antiproliferative activity
not only against lymphocytes but also against vascular cells,
in vitro and in vivo in MCT-induced PAH [43].
(6) Granulocyte colony-stimulating factor inhibited the
progression of PAH in a rat model, possibly by stimulating
pulmonary endothelial cells to proliferate at sites of impaired
lung vasculature [44].
(7) The NF-κB nuclear localization and vascular cell
adhesion molecule (VCAM-1) expression are temporally
and spatially associated with the development of MCT-
induced PAH in rats. Administration of a NF−κB inhibitor,
pyrrolidine dithiocarbamate, reversed the MCT-induced
development of PAH in rats [45].
(8) In rats with MCT-induced PAH treatment with an
interleukin-1 receptor antagonist started at the same time as
MCT administration and continued for the ﬁrst 2 weeks
prevented the development of PAH and RV hypertrophy as
assessed 3 weeks after MCT injection [46].
(9) In rats with MCT-induced PAH, treatment with anti-
bodiestomonocytechemotacticandactivatingfactor/monocyte
chemoattractant protein-1 was started at the same time as
MCT administration or at day 3.5, 7, or 14 after MCT
administration.AntibodytherapystartedtogetherwithMCT
administration was the most eﬀective in alleviating RV
hypertrophy, as compared to later starts [47]. Antibody
therapy started together with MCT administration did not
prevent development of pulmonary hypertension, but RV
peak systolic pressure was signiﬁcantly lower than observed
in rats treated with MCT only.
(10) One day after MCT administration (60mg/kg), rats
were treated without or with a speciﬁc inhibitor of p38
mitogen-activated protein kinase, FR167653, for 27 days. Four
weeks after MCT administration pulmonary artery pressure
and RV weight had hardly increased, compared to rats that
received only MCT. The beneﬁcial eﬀects of FR167653 were
ascribedtoattenuatedexpressionofinﬂammatorycytokines,
thereby preventing the progression of PAH [48].
(11) PAH is associated with endothelial injury [49]
and with NO-dependent endothelial dysfunction [50]. Rats
treated with daily i.p. doses of L-arginine (500mg/kg),
started 3 days before MCT administration, and continuing
till sacriﬁce of the animals at day 17 after MCT injection,
prevented the development of PAH, RV hypertrophy, and
pulmonary vascular disease [51].
(12) Rats were, 2 days before MCT administration
(60mg/kg), treated without or with an i n h i b i t o ro fl i p o x y g e -
nase pathways, diethylcarbamazine, for 23 days. Three weeks
after MCT administration, therapy with diethylcarbamazineJournal of Biomedicine and Biotechnology 5
had blocked the development of PAH and RV hypertrophy,
associated with inhibition of inﬂux of polymorphonuclear
cells and alveolar macrophages into the alveoli and the
activation of these cells by lipoxygenase-related products
[52].
(13) Therapy of rats with MCT-induced PAH was started
3 weeks later using daily i.p. injections of the activin receptor-
like kinase-5 signaling inhibitor IN-1233 for an additional
2 weeks. At that time RV peak systolic pressure and RV
hypertrophy index were signiﬁcantly lower in the treated rats
than in the untreated rats with PAH [53].
2.2. Gene Therapy
2.2.1. Extracellular Superoxide Dismutase Gene. There is
ample evidence that oxidative stress contributes to the
pathogenesis and/or development of PAH. MCT-injected
rats were intratracheally administered (1) vehicle (MCT
group), (2) an adenovirus encoding β-galactosidase (Adβgal
group), or (3) an adenovirus encoding human extracel-
lular superoxide dismutase (EC-SOD) (AdEC-SOD group).
After intratracheal gene transfer, EC-SOD was successfully
expressed in lung tissue, bronchoalveolar lavage ﬂuid, and
plasma. Twenty-eight days after MCT injection, RV systolic
pressure and the weight ratio of the RV to the LV plus
septum were signiﬁcantly lower in the AdEC-SOD group
than in the MCT group and the Adβgal group. Moreover,
vascular remodeling and proliferation of vascular SMCs in
pulmonary arteries were markedly suppressed in the AdEC-
SOD group [54].
2.2.2. Plasmid Inhibiting MCP-1. Monocyte/macrophage
chemoattractant protein-1 (MCP-1) is a potent chemoat-
tractant chemokine and an activator for mononuclear cells.
Intramuscular injection of a plasmid encoding a 7-terminal
deleted dominant negative inhibitor of MCP-1 in rats simul-
taneously injected with MCT inhibited the progression of
MCT-induced PAH, RV hypertrophy, medial hypertrophy of
pulmonary arterioles, and mononuclear cell inﬁltration into
the lungs [55].
2.2.3. Prostacyclin Synthase Gene. Prostacyclin is a potent
vasodilator that also inhibits platelet adhesion and cell
growth. Intratracheal transfer of the human prostacyclin
synthase (PGIS) gene to rats with MCT-induced PAH
augmented pulmonary prostacyclin synthesis, ameliorated
MCT-induced PAH, and improved survival in MCT rats
[56]. An intramuscular injection of adeno-associated virus
(AAV) vector harboring the PGIS gene (AAV-PGIS) also
prevented MCT-induced PAH in rats [57].
2.2.4. Angiopoietin-1 Gene. Cell-based gene transfer with
angiopoietin-1 (Ang-1), a newly discovered ligand of the
endothelial-speciﬁc tyrosine kinase receptor Tie-2, has been
showntoimprovesurvivalandpulmonaryhemodynamicsin
experimental PAH by a mechanism involving the inhibition
of apoptosis and protection of the pulmonary microvascula-
ture [58].
2.2.5.Interleukin-10Gene. Interleukin(IL)-10isapleiotropic
anti-inﬂammatory cytokine with vasculoprotective proper-
ties. After rats were injected intramuscularly with an AAV
serotype 1 vector expressing IL-10, followed by MCT injec-
tion, it was demonstrated that IL-10 expression prevented
MCT-induced PAH in rats [59].
2.3. Cell Therapy
2.3.1. Intratracheal Mesenchymal Stem Cell Therapy. Rat
bone marrow-derived mesenchymal stem cells (rMSCs)
transfected with the lacZ gene were administered intra-
tracheally to rats 2 weeks after administration of MCT.
Intratracheal cell therapy attenuated the rise in pulmonary
arterial pressure and pulmonary vascular resistance and
restored pulmonary responses to acetylcholine toward val-
ues measured in control rats. Treatment with rMSCs
decreased RV hypertrophy induced by PAH. Immunohisto-
chemical studies showed widespread distribution of lacZ-
labeled rMSCs in lung parenchyme surrounding airways
in MCT-treated rats. These rMSCs retained the expres-
sion of von Willebrand factor and α-smooth muscle-
actin, being markers speciﬁc for endothelial cell and
SMC phenotypes, respectively. However, lacZ expressing
rMSCs were not detected in the wall of pulmonary vessels
[60].
2.3.2. Intravenous Administration of Pulmonary Artery
Smooth Muscle Cells. Primary cultures of rat PA-SMCs were
transfected with either the full-length coding sequence of
the eNOS gene or with the control vector. Transfected PA-
SMCs were delivered to syngeneic recipient rats by injection
into the jugular vein, simultaneously with MCT. At 28 d
afterinjection,ratsinjectedwiththeeNOS-transfectedSMCs
had signiﬁcantly lower RV systolic pressure than rats injected
withthenull-transfectedSMCs[61].CulturedPA-SMCsthat
were in vitro transfected with the gene encoding vascular
endothelial growth factor (VEGF)-A were administered i.v.
to rats simultaneously with MCT injection. Four weeks
later, PAH, RV hypertrophy, and medial hypertrophy of
pulmonary arterioles were signiﬁcantly less in the VEGF-
treated animals compared to MCT-treated animals that
did not receive cell therapy. If cell-based gene transfer
using VEGF-expressing PA-SMCs was delayed till PAH had
developed, also a signiﬁcant decrease in the progression of
PAH and RV hypertrophy was documented [62]. Thus, a
therapeutic role for angiogenic factors in the therapy of PAH
is very likely.
2.3.3. Intravenous Administration of Fibroblasts. Twenty one
days after MCT injection, rats received i.v. (1) ﬁbroblasts
transfected with the eNOS gene, (2) ﬁbroblasts transfected
with the VEGF-A gene, and (3) null-transfected ﬁbroblasts.
Fourteen days later it appeared that eNOS-transfected
ﬁbroblasts reduced pulmonary artery pressure; whereas
VEGF-transfected ﬁbroblasts prevented further increases of
pulmonary artery pressure but did not reverse established
PAH [63].6 Journal of Biomedicine and Biotechnology
2.3.4. Intravenous Administration of Endothelial Progenitor
Cells. Rat bone marrow-derived endothelial progenitor cells
(EPCs), cultured for 7 to 10 days in endothelial growth
medium and injected i.v. in syngeneic MCT-treated rats,
engrafted at the level of the distal pulmonary arterioles
and incorporated into the endothelial lining of the MCT-
injured lung. The administration of EPCs 3 days after MCT
administration nearly completely prevented the increase in
RV pressure observed at 3 weeks with MCT alone. Delayed
administration of EPCs 3 weeks after MCT prevented the
further progression of PAH 2 weeks later; whereas animals
receiving EPCs transfected with the human eNOS gene
exhibited signiﬁcant regression of established disease at
day 35 compared with day 21. Moreover, the delivery of
EPCs to rats with established PAH resulted in marked
improvementinsurvival,whichwasthegreatestinthegroup
receiving eNOS-transduced EPCs [64]. In a study by Yip and
coworkers EPCs were harvested from bone marrow 7 days
after MCT injection (75mg/kg) [65]. The EPCs were grown
in vitro for 3 weeks and then administered, after labeling,
intravenously at day 28 in the rat from which the EPCs
were isolated. The ﬁnal analysis was done at day 90. Labeled
EPCs were recovered in the endothelial lining of distal
pulmonary arterioles, where they may have diﬀerentiated
into mature endothelial cells and restored the integrity of
vascular endothelial function. The i.v. administration of
autologous EPCs led to reduced (i) RV hypertrophy, (ii)
RV systolic pressure, and (iii) wall thickening of pulmonary
arterioles, associated with increased pulmonary arteriolar-
capillary density, although most values remained diﬀerent
from those of healthy rats.
2.3.5. Intravenous Administration of Bone Marrow-Derived
Cells. The recent evidence suggests that bone marrow-
derived cells may diﬀerentiate into vascular cells that partici-
pateinarterialrepairand/orlesionformation[66].However,
it remains uncertain whether bone marrow-derived cells can
also participate in vascular remodeling associated with PAH.
The bone marrow of Sprague-Dawley rats was reconstituted
with that of green ﬂuorescent protein- (GFP-) transgenic
rats.Thebonemarrow-chimeric ratswereinjected intraperi-
toneally with 60mg/kg MCT after unilateral pneumonec-
tomy.After28days,theyhadRVpeaksystolicpressuresmore
than 2 times the pressure in control animals. The pulmonary
arterioles were markedly thickened, with an inﬁltration of
GFP-positive macrophages into the perivascular areas. The
endothelium of pulmonary arterioles contained only a few
GFP-positive cells, and hardly any GFP–positive cells were
detected in the media of thickened pulmonary arterioles
[67].Thus,unfractionatedbonemarrow-derivedcellsdonot
contribute substantially to pulmonary arterial remodeling
associated with MCT-induced PAH in pneumonectomized
rats.
In another study the eﬀect of bone marrow-derived
cells on PAH induced by either MCT or exposure to
chronic hypoxia in mice was investigated. I.v. admin-
istration of the active MCT metabolite (monocrotaline
pyrrole, MCTp) to mice induced PAH within 15 days,
due to remodeling of small pulmonary arterioles. Three
days after MCTp injection, the mice were injected with
bone marrow-derived cells of donor mice treated with 5-
ﬂuorouracil (3.5mg i.p./animal) to deplete mature cells and
to allow proliferation of progenitor cells. Bone marrow-
derived cells signiﬁcantly attenuated PAH as assessed by
reductions in RV pressure, RV weight, and percentage of
muscularized pulmonary arterioles, compared to irradiated
bone marrow-derived cells administered to MCTp-treated
animals. In contrast, chronically hypoxic mice subjected to
the same procedure failed to show improvement in PAH
[68].
2.3.6. Intravenous Administration of Mesenchymal Stem Cells
Overexpressing Endothelial Nitric Oxide Synthase (eNOS) .
Bone marrow-derived MSCs transfected by the eNOS gene
(MSCs/eNOS) were studied in rats with MCT-induced PAH.
One week after MCT administration, the rats received
3d i ﬀerent treatments: MSCs (MSC group), MSCs/eNOS,
(MSC/eNOS group), or no treatment (PAH group). As
the negative control, rats received saline instead of MCT
(control group). RV pressures in the MSC and MSC/eNOS
groups were signiﬁcantly lower than in the PAH group,
and RV pressure in the MSC/eNOS group was signiﬁcantly
lower than in the MSC group. Similar results were obtained
with regard to RV hypertrophy in the 3 groups. The
survival time of rats receiving MSCs/eNOS was signiﬁcantly
longer than survival time of PAH rats without treatment
[69].
2.3.7. Transplantation of Endothelial Progenitor Cells into the
Lung. The eﬀects of EPC transplantation into the lungs were
studied in dogs with dehydroMCT-induced PAH. The lung
parenchyme was injected with ex vivo-expanded, autologous
EPCs using a bronchoscope. EPC transplantation resulted in
signiﬁcant improvements in pulmonary artery pressure, pul-
monary vascular resistance and cardiac output. Histological
evaluation revealed improvement in the medial thickness of
the small pulmonary arteries and neovascularization of lung
tissue [70].
2.3.8. Intravenous Administration of MSCs from Donor Rats
Suﬀering with PAH. Recently, we completed a study in
which rats with MCT-induced PAH were, 14 days after
MCT injection, treated with (1) a single i.v. MSC injection
(106 cells/rat) obtained from bone marrow of donor rats
with MCT-induced PAH, mimicking autologous stem cell
therapy, or (2) a single injection with saline. Two weeks later
RV pressures were measured, the rats were sacriﬁced, and
heart and lungs were dissected. The saline-treated MCT rats
developed PAH but in the MSC-treated MCT rats the RV
pressures were signiﬁcantly lower. Accordingly, RV hyper-
trophy in the MSC-treated MCT rats was signiﬁcantly lower
comparedtothePBS-treatedMCTrats.Inthisstudywehave
demonstrated that bone marrow-derived MSCs obtained
from donor rats suﬀering from PAH when administered to
recipient rats with PAH reduceing RV pressure overload and
RV hypertrophy [71].Journal of Biomedicine and Biotechnology 7
Table 1: Classiﬁcation of published therapies of experimental pulmonary hypertension.
(Ref.)
Antimitogenic (particularly towards PA-SMCs)
PDGF inhibitors [4]
Endothelin receptor blockers [16–19, 29]
Prostacyclin (analogue) [5–10, 15, 19]
Serotonin transporter inhibitors [21]
Serotonin receptor blockers [23, 24]
Serotonic re-uptake inhibitor [22]
PDE 4/5 and 3/4 inhibitors [9, 10, 25–29]
Caveolin-1 peptide [30]
Estradiol (derivatives) [31–34]
Amlodipine [38]
Rapamycin [42]
Cell therapy using diﬀerentiated cells transduced with eNOS gene [60, 62, 63, 68]
Prostacyclin synthase gene [55, 56]
NF-κB inhibitor [44]
Serine-elastase inhibitors [3]
Proendothelial function, vasodilatation, and proangiogenesis
Rho-kinase inhibitors [11–15]
Statins [35–37]
Nicorandil [39]
Granulocyte-colony stimulating factor [43]
L-arginine [50]
Prostacyclin (analogue) [5–10, 15, 19]
Endothelin receptor blockers [16–19, 29]
PDE 4/5 and 3/4 inhibitors [9, 10, 25–29]
Adrenomedullin [41]
Prostacyclin synthase gene [55, 56]
Angiopoietin-1 gene [57]
Cell therapy using EPCs and MSCs [59, 63–65, 68–71]
Cell therapy using diﬀerentiated cells transduced with eNOS gene [60, 62, 63, 68]
Cell therapy using diﬀerentiated cells transduced with VEGF gene [61, 62]
Anti-inﬂammatory and antioxidative
Serotonin receptor blockers [23, 24]
Amlodipine [38]
Nicorandil [39]
Statins [35–37]
C-type natriuretic factor [40]
Interleukin-1 receptor antagonist [45]
Antibodies to monocyte chemotactic and activating factor/MCP1 [46]
Inhibitor of p38 mitogen-activated protein kinase [47]
Inhibitor of lipoxygenase pathways [51]
Antimonocyte chemoattractant protein-1 gene [54]
Interleukin-10 gene [58]
Extracellular superoxide dismutase gene [53]
Abbreviations: PA-SMCs: pulmonary artery-derived smooth muscle cells; PDGF: platelet-derived growth factor; PDE: phosphodiesterase; NO: nitrico x i d e ;
EPC:endothelialprogenitorcells;MSC:mesenchymalstemcells;eNOS:endothelialNO-synthase;VEGF:vascularendothelialgrowthfactor;MCP1:monocyte
chemoattractant protein-1.8 Journal of Biomedicine and Biotechnology
3. Cell Therapy for PAH, from
ExperimentalModels to ClinicalDisease
Cell therapy is a promising novel therapeutic option, and
several cell types have been tested in experimental models
of PAH. EPCs have recently been explored as a potential
source for neovascularization of the diseased pulmonary
circulation in patients with PAH. A ﬁrst randomized trial has
indicated that i.v. infusion of autologous EPCs to patients
with idiopathic PAH appears to be feasible and safe and
has beneﬁcial eﬀects on exercise capacity and pulmonary
hemodynamics [72].
Also MSC is a cell type that can improve the pulmonary
pathology of PAH by either diﬀerentiating into other cell
types leading to regeneration of the diseased vasculature or
secreting an array of substances, the “prosurvival factors”
including various growth factors and cytokines, leading to
improvement in lung pathology by paracrine mechanisms.
Autologous bone marrow-derived MSC therapy has a practi-
cal advantage over other types of cell therapies, as the mode
of administration is rather simple and has proven to be safe.
4. Conclusions
In conclusion, a wealth of therapeutic modalities includ-
ing pharmacotherapy, gene therapy, and cell therapy has
been tested in several animal models of PAH. In these
therapeutic modalities we distinguish three approaches: (i)
antiproliferative and proapoptotic therapies towards PA-
SMCs, (ii) therapies that improve endothelial function,
promote angiogenesis, and induce vasodilatation, and (iii)
antiinﬂammatory and antioxidative therapies (seeTable 1 ).
Although many of these therapies have demonstrated to
be eﬀective in monocrotaline-induced PAH in experimental
animals, any therapy to be planned for use in human
PAH should be tested before in other animal models of
PAH. As many patients remain symptomatic despite therapy,
new therapeutic modalities are being developed. As such,
cell therapy is a novel treatment option, and stem cell
therapy is most promising. Although many questions about
optimal cell type, in vitro cell transduction, route of cell
administration, and number of cells to inject are waiting for
answers,weexpectthatautologousMSCtherapyisasafeand
eﬃcacious option to treat patients with PAH.
List of Abbreviations
AAV: Adeno-associated virus
Ang-1: Angiopoietin-1
AP: Drosophila transcription factor atennapedia
ATP: Adenosine triphosphate
cAMP: Cyclic adenosine monophosphate
Cav-1: Caveolin-1
CNP: C-type natriuretic peptide
ECM: Extracellular matrix
EC-SOD: Extracellular superoxide dismutase
eNOS: Endothelial nitric oxide synthase
EPC: Endothelial progenitor cell
ET: Endothelin
G-CSF: Granulocyte colony stimulating factor
AAV: Adeno-associated virus
GFP: Green ﬂuorescent protein
cGMP: Cyclic guanosine monophosphate
GTPase: Guanosine triphosphatase
5-HT: 5-hydroxy tryptamine
5-HTT: 5-hydroxy tryptamine transporter
IL-10: Interleukin-10
MCT: Monocrotaline
MCTp: Monocrotaline pyrrole
2-ME: 2-Methoxyestradiol
MSC: Mesenchymal stem cells
NF-κB: Nuclear factor-κB
PA-SMC: Pulmonary artery smooth muscle cell
PAH: Pulmonary arterial hypertension
PDE: Phosphodiesterase
PDGF: Platelet derived growth factor
PGIS: Prostacyclin synthase
RV: Right ventricle
SMC: Smooth muscle cell
VCAM-1: Vascular cell adhesion molecule-1
VEGF: Vascular endothelial growth factor.
References
[1] B. Sztrymf, A. Yaici, B. Girerd, and M. Humbert, “Genes and
pulmonary arterial hypertension,” Respiration, vol. 74, no. 2,
pp. 123–132, 2007.
[ 2 ]K .N .C o w a n ,P .L .J o n e s ,a n dM .R a b i n o v i t c h ,“ R e g r e s s i o n
of hypertrophied rat pulmonary arteries in organ culture is
associated with suppression of proteolytic activity, inhibition
of tenascin-C, and smooth muscle cell apoptosis,” Circulation
Research, vol. 84, no. 10, pp. 1223–1233, 1999.
[ 3 ]K .N .C o w a n ,P .L .J o n e s ,a n dM .R a b i n o v i t c h ,“ E l a s t a s e
and matrix metalloproteinase inhibitors induce regression,
and tenascin-C antisense prevents progression, of vascular
disease,” Journal of Clinical Investigation, vol. 105, no. 1, pp.
21–34, 2000.
[ 4 ]K .N .C o w a n ,A .H e i l b u t ,T .H u m p l ,C .L a m ,S .I t o ,a n dM .
Rabinovitch, “Complete reversal of fatal pulmonaryhyperten-
sioninratsbyaserineelastaseinhibitor,”Nature Medicine,vol.
6, no. 6, pp. 698–702, 2000.
[5] R. T. Schermuly, E. Dony, H. A. Ghofrani, et al., “Reversal of
experimental pulmonary hypertension by PDGF inhibition,”
Journal of Clinical Investigation, vol. 115, no. 10, pp. 2811–
2821, 2005.
[ 6 ]M .E .v a nA l b a d a ,R .M .F .B e r g e r ,M .N i g g e b r u g g e ,R .
van Veghel, A. H. Cromme-Dijkhuis, and R. G. Schoemaker,
“Prostacyclin therapy increases right ventricular capillarisa-
tion in a model for ﬂow-associated pulmonary hypertension,”
E u r o p e a nJ o u r n a lo fP h a r m a c o l o g y , vol. 549, no. 1–3, pp. 107–
116, 2006.
[7] M. Kataoka, N. Nagaya, T. Satoh, et al., “A long-acting
prostacyclin agonist with thromboxane inhibitory activity for
pulmonaryhypertension,”AmericanJournalofRespiratoryand
Critical Care Medicine, vol. 172, no. 12, pp. 1575–1580, 2005.
[8] H. Obata, Y. Sakai, S. Ohnishi, et al., “Single injection of
a sustained-release prostacyclin analog improves pulmonary
hypertension in rats,” American Journal of Respiratory and
Critical Care Medicine, vol. 177, no. 2, pp. 195–201, 2008.Journal of Biomedicine and Biotechnology 9
[9] R. T. Schermuly, H. Yilmaz, H. A. Ghofrani, et al., “Inhaled
iloprost reverses vascular remodeling in chronic experimental
pulmonaryhypertension,”AmericanJournalofRespiratoryand
Critical Care Medicine, vol. 172, no. 3, pp. 358–363, 2005.
[10] T. Itoh, N. Nagaya, T. Fujii, et al., “A combination of oral
sildenaﬁl and beraprost ameliorates pulmonary hypertension
in rats,” American Journal of Respiratory and Critical Care
Medicine, vol. 169, no. 1, pp. 34–38, 2004.
[11] R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, et
al., “Antiremodeling eﬀects of iloprost and the dual-selective
phosphodiesterase 3/4 inhibitor tolafentrine in chronic exper-
imental pulmonary hypertension,” Circulation Research, vol.
94, no. 8, pp. 1101–1108, 2004.
[12] K. Abe, H. Shimokawa, K. Morikawa, et al., “Long-term treat-
ment with a Rho-kinase inhibitor improves monocrotaline-
induced fatal pulmonary hypertension in rats,” Circulation
Research, vol. 94, no. 3, pp. 385–393, 2004.
[13] K. Abe, S. Tawara, K. Oi, et al., “Long-term inhibition of Rho-
kinase ameliorates hypoxia-induced pulmonary hypertension
in mice,” Journal of Cardiovascular Pharmacology, vol. 48, no.
6, pp. 280–285, 2006.
[14] B. H. Jiang, S. Tawara, K. Abe, A. Takaki, Y. Fukumoto, and H.
Shimokawa, “Acute vasodilator eﬀect of fasudil, a Rho-kinase
inhibitor, in monocrotaline-induced pulmonary hypertension
in rats,” Journal of Cardiovascular Pharmacology, vol. 49, no. 2,
pp. 85–89, 2007.
[15] T. Nagaoka, K. A. Fagan, S. A. Gebb, et al., “Inhaled Rho
kinase inhibitors are potent and selective vasodilators in rat
pulmonaryhypertension,”AmericanJournalofRespiratoryand
Critical Care Medicine, vol. 171, no. 5, pp. 494–499, 2005.
[16] S. Tawara, Y. Fukumoto, and H. Shimokawa, “Eﬀects of com-
bined therapy with a Rho-kinase inhibitor and prostacyclin
on monocrotaline-induced pulmonary hypertension in rats,”
Journal of Cardiovascular Pharmacology, vol. 50, no. 2, pp.
195–200, 2007.
[17] N.S.H ill,R.R.W arb urt o n,L.Pietras,andJ .R.Kling e r ,“N o n-
speciﬁcendothelin-receptorantagonistbluntsmonocrotaline-
induced pulmonary hypertension in rats,” Journal of Applied
Physiology, vol. 83, no. 4, pp. 1209–1215, 1997.
[18] M. Nishida, Y. Okada, K. Akiyoshi, et al., “Role of endothelin
ETB receptor in the pathogenesis of monocrotaline-induced
pulmonary hypertension in rats,” E u r o p e a nJ o u r n a lo fP h a r -
macology, vol. 496, no. 1, pp. 159–165, 2004.
[19] M. Nishida, K. Eshiro, Y. Okada, M. Takaoka, and Y.
Matsumura, “Roles of endothelin ETA and ETB receptors
in the pathogenesis of monocrotaline-induced pulmonary
hypertension,” Journal of Cardiovascular Pharmacology, vol.
44, no. 2, pp. 187–191, 2004.
[20] M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K.
Goto, and I. Yamaguchi, “A combination of oral endothelin-A
receptor antagonist and oral prostacyclin analogue is superior
to each drug alone in ameliorating pulmonary hypertension
in rats,” Journal of the American College of Cardiology, vol. 40,
no. 1, pp. 175–181, 2002.
[21] C. Guignabert, M. Izikki, L. I. Tu, et al., “Transgenic mice
overexpressing the 5-hydroxytryptamine transporter gene in
smoothmuscledeveloppulmonaryhypertension,”Circulation
Research, vol. 98, no. 10, pp. 1323–1330, 2006.
[22] C. Guignabert, B. Raﬀestin, R. Benferhat, et al., “Serotonin
transporter inhibition prevents and reverses monocrotaline-
induced pulmonary hypertension in rats,” Circulation, vol.
111, no. 21, pp. 2812–2819, 2005.
[23] X.-Q. Li, Y. Hong, Y. Wang, X.-H. Zhang, and H.-L.
Wang, “Sertraline protects against monocrotaline-induced
pulmonary hypertension in rats,” Clinical and Experimental
Pharmacology and Physiology, vol. 33, no. 11, pp. 1047–1051,
2006.
[24] M. Miyata, M. Ito, T. Sasajima, H. Ohira, Y. Sato, and
R. Kasukawa, “Development of monocrotaline-induced pul-
monary hypertension is attenuated by a serotonin receptor
antagonist,” Lung, vol. 178, no. 2, pp. 63–73, 2000.
[25] E. Hironaka, M. Hongo, A. Sakai, et al., “Serotonin recep-
tor antagonist inhibits monocrotaline-induced pulmonary
hypertension and prolongs survival in rats,” Cardiovascular
Research, vol. 60, no. 3, pp. 692–699, 2003.
[26] H. Liu, Z.-Y. Liu, and Q. Guan, “Oral sildenaﬁl prevents
and reverses the development of pulmonary hypertension
in monocrotaline-treated rats,” Interactive Cardiovascular and
Thoracic Surgery, vol. 6, no. 5, pp. 608–613, 2007.
[27] E. Dony, Y.-J. Lai, R. Dumitrascu, et al., “Partial reversal of
experimental pulmonary hypertension by phosphodiesterase-
3/4inhibition,”EuropeanRespiratoryJournal,vol.31,no .3,pp .
599–610, 2008.
[28] R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, et
al., “Chronic sildenaﬁl treatment inhibits monocrotaline-
induced pulmonary hypertension in rats,” American Journal
of Respiratory and Critical Care Medicine, vol. 169, no. 1, pp.
39–45, 2004.
[29] S. Pullamsetti, S. Krick, H. Yilmaz, et al., “Inhaled tolafentrine
reverses pulmonary vascular remodeling via inhibition of
smoothmusclecellmigration,”RespiratoryResearch,vol.6,no.
11, p. 128, 2005.
[30] M. Clozel, P. Hess, M. Rey, M. Iglarz, C. Binkert, and C.
Qiu, “Bosentan, sildenaﬁl, and their combination in the
monocrotaline model of pulmonary hypertension in rats,”
Experimental Biology and Medicine, vol. 231, no. 6, pp. 967–
973, 2006.
[31] J.-F. Jasmin, I. Mercier, J. Dupuis, H. B. Tanowitz, and
M. P. Lisanti, “Short-term administration of a cell-
permeable caveolin-1 peptide prevents the development
of monocrotaline-induced pulmonary hypertension and right
ventricular hypertrophy,” Circulation, vol. 114, no. 9, pp.
912–920, 2006.
[32] N. Homma, Y. Morio, H. Takahashi, et al., “Genistein, a
phytoestrogen, attenuates monocrotaline-induced pulmonary
hypertension,” Respiration, vol. 73, no. 1, pp. 105–112, 2006.
[33] S. P. Tofovic, E. M. Salah, H. H. Mady, E. K. Jackson, and M.
F. Melhem, “Estradiol metabolites attenuate monocrotaline-
induced pulmonary hypertension in rats,” Journal of Cardio-
vascular Pharmacology, vol. 46, no. 4, pp. 430–437, 2005.
[34] S. P. Tofovic, X. Zhang, E. K. Jackson, S. Dacic, and
G. Petrusevska, “2-methoxyestradiol mediates the protective
eﬀects of estradiol in monocrotaline-induced pulmonary
hypertension,” Vascular Pharmacology, vol. 45, no. 6, pp. 358–
367, 2006.
[35] S. P. Tofovic, X. Zhang, H. Zhu, E. K. Jackson, O. Raﬁkova,
and G. Petrusevska, “2-ethoxyestradiol is antimitogenic and
attenuates monocrotaline-induced pulmonary hypertension
and vascular remodeling,” Vascular Pharmacology, vol. 48, no.
4–6, pp. 174–183, 2008.
[36] T. Nishimura, J. L. Faul, G. J. Berry, et al., “Simvastatin attenu-
ates smooth muscle neointimal proliferation and pulmonary
hypertension in rats,” American Journal of Respiratory and
Critical Care Medicine, vol. 166, no. 10, pp. 1403–1408, 2002.
[37] P. Guerard, Z. Rakotoniaina, F. Goirand, et al., “The HMG-
CoA reductase inhibitor, pravastatin, prevents the develop-
ment of monocrotaline-induced pulmonary hypertension in
the rat through reduction of endothelial cell apoptosis and10 Journal of Biomedicine and Biotechnology
overexpression of eNOS,” Naunyn-Schmiedeberg’s Archives of
Pharmacology, vol. 373, no. 6, pp. 401–414, 2006.
[38] X. Sun and D. D. Ku, “Rosuvastatin provides pleiotropic
protection against pulmonary hypertension, right ventricular
hypertrophy, and coronary endothelial dysfunction in rats,”
American Journal of Physiology, vol. 294, no. 2, pp. H801–
H809, 2008.
[39] E. Mawatari, M. Hongo, A. Sakai, et al., “Amlodipine prevents
monocrotaline-induced pulmonary arterial hypertension and
prolongs survival in rats independent of blood pressure lower-
ing,” Clinical and Experimental Pharmacology and Physiology,
vol. 34, no. 7, pp. 594–600, 2007.
[40] M. Hongo, E. Mawatari, A. Sakai, et al., “Eﬀects of nicorandil
on monocrotaline-induced pulmonary arterial hypertension
in rats,” Journal of Cardiovascular Pharmacology, vol. 46, no. 4,
pp. 452–458, 2005.
[41] T. Itoh, N. Nagaya, S. Murakami, et al., “C-type natri-
ureticpeptideamelioratesmonocrotaline-inducedpulmonary
hypertension in rats,” American Journal of Respiratory and
Critical Care Medicine, vol. 170, no. 11, pp. 1204–1211, 2004.
[42] N. Nagaya, H. Okumura, M. Uematsu, et al., “Repeated
inhalation of adrenomedullin ameliorates pulmonary hyper-
tension and survival in monocrotaline rats,” American Journal
of Physiology, vol. 285, no. 5, pp. H2125–H2131, 2003.
[ 4 3 ]H .Z h o u ,H .L i u ,S .L .P o r v a s n i k ,e ta l . ,“ H e m eo x y g e n a s e -
1 mediates the protective eﬀects of rapamycin in
monocrotaline-inducedpulmonaryhypertension,”Laboratory
Investigation, vol. 86, no. 1, pp. 62–71, 2006.
[44] H. Maruyama, S. Watanabe, T. Kimura, et al., “Gran-
ulocyte colony-stimulating factor prevents progression of
monocrotaline-induced pulmonary arterial hypertension in
rats,” Circulation Journal, vol. 71, no. 1, pp. 138–143, 2007.
[45] H. Sawada, Y. Mitani, J. Maruyama, et al., “A nuclear factor-κB
inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary
hypertension in rats,” Chest, vol. 132, no. 4, pp. 1265–1274,
2007.
[46] N. F. Voelkel, R. M. Tuder, J. Bridges, and W. P. Arend,
“Interleukin-1 receptor antagonist treatment reduces pul-
monary hypertension generated in rats by monocrotaline,”
AmericanJournalofRespiratoryCellandMolecularBiology,vol.
11, no. 6, pp. 664–675, 1994.
[47] H. Kimura, Y. Kasahara, K. Kurosu, et al., “Alleviation of
monocrotaline-induced pulmonary hypertension by antibod-
ies to monocyte chemotactic and activating factor/monocyte
chemoattractant protein-1,” Laboratory Investigation, vol. 78,
no. 5, pp. 571–581, 1998.
[48] J. Lu, H. Shimpo, A. Shimamoto, et al., “Speciﬁc inhibition
of p38 mitogen-activated protein kinase with FR167653
attenuates vascular proliferation in monocrotaline-induced
pulmonary hypertension in rats,” Journal of Thoracic and
Cardiovascular Surgery, vol. 128, no. 6, pp. 850–859, 2004.
[49] H. C. Rosenberg and M. Rabinovitch, “Endothelial injury
and vascular reactivity in monocrotaline pulmonary hyper-
tension,” American Journal of Physiology, vol. 255, no. 6, pp.
H1484–H1491, 1988.
[50] J. Maruyama and K. Maruyama, “Impaired nitric oxide-
dependent responses and their recovery in hypertensive
pulmonary arteries of rats,” American Journal of Physiology,
vol. 266, no. 6, pp. H2476–H2488, 1994.
[51] Y. Mitani, K. Maruyama, and M. Sakurai, “Prolonged
administration of L-arginine ameliorates chronic pulmonary
hypertension and pulmonary vascular remodeling in rats,”
Circulation, vol. 96, no. 2, pp. 689–697, 1997.
[52] K. R. Stenmark, M. L. Morganroth, L. K. Remigio, et
al., “Alveolar inﬂammation and arachidonate metabolism in
monocrotaline-induced pulmonary hypertension,” American
Journal of Physiology, vol. 248, no. 6, pp. H859–H866, 1985.
[53] L. Long, A. Crosby, X. Yang, et al., “Altered bone morpho-
genetic protein and transforming growth factor-β signaling
in rat models of pulmonary hypertension: potential for
activin receptor-like kinase-5 inhibition in prevention and
progression of disease,” Circulation, vol. 119, no. 4, pp. 566–
576, 2009.
[54] F. Kamezaki, H. Tasaki, K. Yamashita, et al., “Gene transfer
of extracellular superoxide dismutase ameliorates pulmonary
hypertension in rats,” American Journal of Respiratory and
Critical Care Medicine, vol. 177, no. 2, pp. 219–226, 2008.
[55] Y. Ikeda, Y. Yonemitsu, C. Kataoka, et al., “Anti-monocyte
chemoattractant protein-1 gene therapy attenuates pul-
monary hypertension in rats,” American Journal of Physiology,
vol. 283, no. 5, pp. H2021–H2028, 2002.
[56] N. Nagaya, C. Yokoyama, S. Kyotani, et al., “Gene transfer
of human prostacyclin synthase ameliorates monocrotaline-
induced pulmonary hypertension in rats,” Circulation, vol.
102, no. 16, pp. 2005–2010, 2000.
[57] T. Ito, T. Okada, J. Mimuro, et al., “Adenoassociated virus-
mediated prostacyclin synthase expression prevents pul-
monary arterial hypertension in rats,” Hypertension, vol. 50,
no. 3, pp. 531–536, 2007.
[ 5 8 ]Y .D .Z h a o ,A .I .M .C a m p b e l l ,M .R o b b ,D .N g ,a n dD .J .
Stewart, “Protective role of angiopoietin-1 in experimental
pulmonary hypertension,” Circulation Research, vol. 92, no. 9,
pp. 984–991, 2003.
[59] T. Ito, T. Okada, H. Miyashita, et al., “Interleukin-10 expres-
sion mediated by an adeno-associated virus vector prevents
monocrotaline-induced pulmonary arterial hypertension in
rats,” Circulation Research, vol. 101, no. 7, pp. 734–741, 2007.
[60] S. R. Baber, W. Deng, R. G. Master, et al., “Intratracheal mes-
enchymal stem cell administration attenuates monocrotaline-
induced pulmonary hypertension and endothelial dysfunc-
tion,” American Journal of Physiology, vol. 292, no. 2, pp.
H1120–H1128, 2007.
[61] A. I. M. Campbell, M. A. Kuliszewski, and D. J. Stewart, “Cell-
based gene transfer to the pulmonary vasculature. Endothelial
nitric oxide synthase overexpression inhibits monocrotaline-
induced pulmonary hypertension,” American Journal of Respi-
ratory Cell and Molecular Biology, vol. 21, no. 5, pp. 567–575,
1999.
[62] A. I. M. Campbell, Y. Zhao, R. Sandhu, and D. J. Stewart,
“Cell-basedgenetransferofvascularendothelialgrowthfactor
attenuates monocrotaline-induced pulmonary hypertension,”
Circulation, vol. 104, no. 18, pp. 2242–2248, 2001.
[ 6 3 ]Y .D .Z h a o ,D .W .C o u r t m a n ,D .S .N g ,e ta l . ,“ M i c r o v a s c u l a r
regenerationinestablishedpulmonaryhypertensionbyangio-
genic gene transfer,” American Journal of Respiratory Cell and
Molecular Biology, vol. 35, no. 2, pp. 182–189, 2006.
[64] Y. D. Zhao, D. W. Courtman, Y. Deng, L. Kugathasan, Q.
Zhang, and D. J. Stewart, “Rescue of monocrotaline-induced
pulmonary arterial hypertension using bone marrow-derived
endothelial-like progenitor cells: eﬃcacy of combined cell
and eNOS gene therapy in established disease,” Circulation
Research, vol. 96, no. 4, pp. 442–450, 2005.
[65] H. K. Yip, L. T. Chang, C. K. Sun, et al., “Autologous trans-
plantation of bone marrow-derived endothelial progenitor
cells attenuates monocrotaline-induced pulmonary arterial
hypertension in rats,” Critical Care Medicine, vol. 36, no. 3, pp.
873–880, 2008.Journal of Biomedicine and Biotechnology 11
[66] T.AsaharaandA.Kawamoto,“Endothelial progenitorcellsfor
postnatal vasculogenesis,” American Journal of Physiology, vol.
287, no. 3, pp. C572–C579, 2004.
[67] M. Sahara, M. Sata, T. Morita, K. Nakamura, Y. Hirata, and
R. Nagai, “Diverse contribution of bone marrow-derived cells
to vascular remodeling associated with pulmonary arterial
hypertension and arterial neointimal formation,” Circulation,
vol. 115, no. 4, pp. 509–517, 2007.
[68] W. Raoul, O. Wagner-Ballon, G. Saber, et al., “Eﬀects of
bone marrow-derived cells on monocrotaline- and hypoxia-
induced pulmonary hypertension in mice,” Respiration
Research, vol. 8, no. 1, p. 8, 2007.
[69] S. Kanki-Horimoto, H. Horimoto, S. Mieno, et al., “Implan-
tation of mesenchymal stem cells overexpressing endothelial
nitric oxide synthase improves right ventricular impairments
caused by pulmonary hypertension,” Circulation, vol. 114,
supplement 1, pp. I181–I185, 2006.
[70] M. Takahashi, T. Nakamura, T. Toba, N. Kajiwara, H. Kato,
and Y. Shimizu, “Transplantation of endothelial progenitor
cells into the lung to alleviate pulmonary hypertension in
dogs,” Tissue Engineering, vol. 10, no. 5-6, pp. 771–779, 2004.
[71] S. Umar, Y. P. de Visser, P. Steendijk, et al., “Allogenic stem
cell therapy improves right ventricular function by improving
lung pathology in rats with pulmonary hypertension,” Amer-
ican Journal of Physiology, vol. 297, no. 5, pp. H1606–H1616,
2009.
[72] X.-X. Wang, F.-R. Zhang, Y.-P. Shang, et al., “Transplantation
of autologous endothelial progenitor cells may be beneﬁcial
in patients with idiopathic pulmonary arterial hypertension,”
Journal of the American College of Cardiology, vol. 49, no. 14,
pp. 1566–1571, 2007.